ProCE Banner Activity

Updates on Investigational Microbiome-Directed Therapies for Recurrent C Difficile Infection From IDWeek 2021

Conference Coverage
Clinical Thought
Studies at IDWeek 2021 show that investigational microbiome-directed therapies are efficacious and positively impact quality of life for patients with recurrent C difficile infection. Here is why I am looking forward to using these therapies in my practice.

Released: December 23, 2021

Expiration: December 22, 2022

No longer available for credit.

Share

Faculty

Teena Chopra

Teena Chopra, MD, MPH

Professor, Infectious Diseases
Wayne State University
Corporate Medical Director
Infection Prevention
Hospital Epidemiology
Detroit Medical Center
Detroit, Michigan

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Ferring Pharmaceuticals, Inc.

Faculty Disclosure

Primary Author

Teena Chopra, MD, MPH

Professor, Infectious Diseases
Wayne State University
Corporate Medical Director
Infection Prevention
Hospital Epidemiology
Detroit Medical Center
Detroit, Michigan

Teena Chopra, MD, MPH, has disclosed that she has received contracted research support from Cepheid and Ferring; has received consulting fees from Cepheid, Ferring, Merck, Pfizer, and Shionogi; and has received fees for non-CME services from AbbVie, Cepheid, Ferring, Pfizer, and Shionogi.